e-ISSN 1694-2078
p-ISSN 1694-2086

Arch Med Biomed Res. 2014;1:147-155. doi:10.4314/ambr.v1i4.4

Sajal Kumar Saha1, Jayanta Kishor Chakrabarty2, Sreedam Chandra Das1, Tasfina Islam3, Sitesh Chandra Bachar3

Author Affiliations

1Department of Clinical Pharmacy and Pharmacology, University of Dhaka, Bangladesh
2Department of Pharmacy, BRAC University, Bangladesh
3Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Bangladesh

correspondence to
Sitesh Chandra Bachar; bacharsc63@gmail.com

Received: July 18, 2014
Revised: September 9, 2014
Accepted: September 10, 2014


The pharmacokinetics of omeprazole pharmaceutical products Proceptin® 20mg capsule and Losec® 20mg MUPS tablet were compared in healthy subjects. The study was an open-label, randomized, two-treatment, two-sequence, two-way crossover, single-dose bioavailability study conducted under fasting conditions with a wash out period of seven days between the two administrations. Blood samples were collected pre-dosing and at 0.5–24.0 h post administration of a single oral dose of either of the formulation followed by HPLC analysis. Twenty-eight healthy male subjects (20-28 years) participated in the study. Only four subjects dropped from the study and the other 24 completed the study and were included in the pharmacokinetic and statistical analysis. Evaluated mean (±SD) values of prime pharmacokinetic parameters for reference and test products were Cmax - 345.28 (±42.38) and 316.23 (±26.12) ng/mL, tmax - 2.28 (±0.16) and 2.69 (±0.23) h, AUC0-24 - 710.01 (±92.51) and 771.13 (±102.35) h-ng/ml and AUC0-∞ - 848.21 (±65.31) and 902.56 (±45.23) h.ng/mL, respectively with no significant (p>0.05) differences in paired t-test. Moreover, 90% CI for the AUC0-24, and Cmax values were 89.245-103.154% and 81.634-102.211% respectively were within the predetermined FDA bioequivalence range of 80–125%. On the basis of the pharmacokinetic parameters AUC0-24, the relative bioavailability of the test preparation Proceptin 20 capsule was 108.61% of that of the reference preparation Losec 20mg MUPS tablet. This study stipulated that, the test and reference formulations of omeprazole meet the regulatory criteria for bioequivalence. Thus the test product Proceptin® 20mg may be supplanted for reference product Losec® 20mg MUPS tablet in oral administration.

KEY WORDS: Omeprazole; Cross-over design; HPLC; Comparative pharmacokinetics


CrossRef Link


This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.